PvP Biologics launches Phase 1 trials for celiac disease candidate Kuma062
PvP Biologics, a US-based pharmaceutical company, has recently begun two phase 1 clinical trials to assess the safety, tolerability, and pharmacodynamics of Kuma062, a promising new treatment for celiac disease. These trials are being conducted at Michigan Medicine at the University of Michigan and in Anaheim, involving approximately 80 adult participants. Kuma062 is engineered to […]